Published in Int J Surg Case Rep on October 22, 2016
The SCARE Statement: Consensus-based surgical case report guidelines. Int J Surg (2016) 20.35
Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev (2003) 2.96
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst (2012) 1.78
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol (2014) 1.27
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab (2008) 1.14
Prognostic value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score) tests to separate benign from malignant neoplasms. Tunis Med (2013) 0.99
Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol (2014) 0.92
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer (2014) 0.90
Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) (2014) 0.85
Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbecks Arch Surg (2015) 0.83
Pheochromocytoma diagnosed pathologically with previous negative serum markers. J Surg Oncol (2015) 0.82
Metastatic pheochromocytoma and paraganglioma. Eur J Clin Invest (2015) 0.80
Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience. J Surg Oncol (2015) 0.80